these reasons, CAR-T cell therapy has limited therapeutic efficacy in the clinical application of solid tumors compared to hematologic malignancies [188,189]. Recent studies have shown that CAR-T cell-derived exosomes as a cell-free therapy not only retain most of the functions of CAR-T cells ...
Combination therapy using BRAF and MEK inhibitors increases the effectiveness of these drugs and postpones the emergence of resistance. This type of combined therapy decreased the probability of additional cancers caused by the treatment without raising the incidence of other severe toxicities [32]. Cur...
More radicle strategies for depleting TAMs are also under investigation. Several molecules and mAbs targeting the CSF-1/CSF-1R signaling axis are in clinical development as monotherapy and combined therapy. Inhibitors of the (CSF-1R) (anti-CSF1R antibody-like Cabiralizumab, SNDX-6352, BLZ945, ...
Nahta R, Esteva FJ: HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 2006, 8: 215-10.1186/bcr1612. PubMed PubMed Central Google Scholar Abdel-Razeq H, Marei L: Current neoadjuvant treatment options for HER2-positive breast cancer. Biologics. 2011, 5: 87-94...
Considering the increasing incidences of therapy induced NEPC, the proposed project will have significant implications and will impact the clinical management of NEPC. Methods Cell lines and cell culture Human embryonic kidney 293T (HEK293T) cells and prostate cancer cell lines Du145, LNCaP, NCI-...
Using mRNA therapy increases precision and specificity [87]. Preclinical studies have demonstrated the benefits of exosome-based mRNA therapies, which are moving toward clinical trials [88]. In clinical applications, exosomes are a promising vehicle for delivering mRNA. The use of exosomes as mRNA ...
The clinical trial (NCT03575598) assessing the neoadjuvant therapy of sitravatinib and nivolumab in oral cancer demonstrated that sitravatinib induced the transition of TAMs from a polarized state to an immunostimulatory phenotype. The TME experienced a reduction in MDSCs, accompanied by an increase...
Harnessing the exosome-induced immune response for cancer immu- notherapy. Semin Cancer Biol 2014; 28C:58-67.Gehrmann, U.; Naslund, T.I.; Hiltbrunner, S.; Larssen, P.; Gabrielsson, S. Harnessing the exosome-induced immune response for cancer immunotherapy. Semin. Cancer Biol. 2014, 28,...
The Efficacy and Safety of Thrice vs Twice per Week Low-Intensity Pulsed Ultrasound Therapy for Erectile Dysfunction: A Randomized Clinical Trial 2022, Journal of Sexual Medicine Citation Excerpt : The existing literature supports the use of low-intensity extracorporeal shockwave therapy (Li-ESWT) and...
MSC therapy was well tolerated, the trial demonstrated feasibility and short-term safety in preterm neonates and phase II trials are now in progress. Although functional end points are beyond the scope of phase I clinical trials, it was noticed that MSC administration was associated with a ...